- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02579239
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)
September 26, 2023 updated by: aTyr Pharma, Inc.
An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies
The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with LGMD2B and FSHD.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
ATYR1940-C-004 is a Phase1b/2 open-label intrapatient study dose escalation study aiming to evaluate the safety, tolerability, immunogenicity, biological activity of intravenous ATYR1940, administered once weekly for 8 weeks, then twice a weekly for 4 weeks in adult patients with LGMD2B and FSHD.
Approximately 8 LGMD2B and 8 FHSD patients will be enrolled.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark
- Rigshospitalet, University of Copenhagen
-
-
-
-
-
Marseille, France, 13385
- Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET)
-
Paris, France
- Institut de Myologie, Hôpital Pitié-Salpêtrière
-
-
-
-
California
-
Irvine, California, United States, 92697
- University of California, Irvine, ALS and Neuromuscular Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Kennedy Krieger Institute; The Johns Hopkins University School of Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- OSU Wexner Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provided informed consent.
- Investigator's opinion, participant is willing and able to complete all study procedures and comply with the study visit schedule.
Participant with LGMD2B:
- Established, genetically confirmed diagnosis of LGMD2B.
- Either the presence of a short tau inversion recovery (STIR) positive muscle on lower extremity skeletal muscle magnetic resonance imaging (MRI), or, if no STIR positive muscles, meets muscle biomarker criteria.
Participant with FSHD:
- Established, genetically confirmed diagnosis of FSHD.
- The presence of a STIR positive muscle on lower extremity skeletal muscle MRI.
Exclusion Criteria:
- Currently receiving treatment with an immunomodulatory agent, including targeted biological therapies within the 3 months before baseline; corticosteroids within 3 months before baseline; or high-dose non-steroidal anti-inflammatory agents within 2 weeks before baseline.
- Currently receiving curcumin or albuterol; use of a product that putatively enhances muscle growth on a chronic basis within 30 days before baseline; statin treatment initiation or significant adjustment to statin regimen within 3 months before baseline (stable, chronic statin use is permissible).
- Use of an investigational product or device within 30 days before baseline.
- Evidence of an alternative diagnosis other than LGMD2B or FSHD or a coexisting myopathy or dystrophy, based on prior muscle biopsy or other available investigations.
- History of severe restrictive or obstructive lung disease or evidence for interstitial lung disease on screening chest radiograph.
- History of anti-synthetase syndrome, prior Jo-1 Ab-positivity, or a positive or equivocally positive Jo-1 Ab test result during screening.
- Chronic infection, such as hepatitis B, hepatitis C, or human immunodeficiency virus or a history of tuberculosis.
- Vaccination within 8 weeks before baseline or vaccination is planned during study participation.
- Symptomatic cardiomyopathy or severe cardiac arrhythmia that may in the Investigator's opinion, limit the participant's ability to complete the study protocol.
- Muscle biopsy within 30 days before baseline.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A - FSHD
Participants with FSHD will receive single dose of placebo intravenous (IV) infusion followed by ATYR1940 IV infusion at doses of 0.3 up to 1.0 milligrams/kilograms (mg/kg) once weekly for 8 weeks and then twice weekly for 4 weeks using intraparticipant dose escalation for up to 12 weeks.
|
Concentrate for solution for infusion
Concentrate for solution for infusion
|
Experimental: Group B - LGMD2B and FSHD
Participants with LGMD2B and FSHD will receive single dose of placebo IV infusion followed by ATYR1940 IV infusion at doses of 0.3 up to 1.0 and 3.0 mg/kg once weekly for 8 weeks and then twice weekly for 4 weeks using intraparticipant dose escalation for up to 12 weeks.
|
Concentrate for solution for infusion
Concentrate for solution for infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to End of Study (up to Week 25)
|
TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug.
An AE was defined as any untoward medical occurrence in a participant administered study drug and that does not necessarily have a causal relationship with the study drug.
Worsening of a pre-existing medical condition should have been considered an AE if there was either an increase in severity, frequency, or duration of the condition or an association with significantly worse outcomes.
An SAE was defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event.
A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.
|
Up to End of Study (up to Week 25)
|
Number of Participants With a Clinically Significant Electrocardiogram (ECG) Abnormality Leading to a TEAE
Time Frame: Up to End of Study (up to Week 25)
|
ECG parameters that were evaluated included heart rate, PR, and QR and QT intervals.
A clinically significant ECG abnormality was based upon the Investigator's discretion.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
|
Up to End of Study (up to Week 25)
|
Number of Participants With a Clinically Significant Pulmonary Function Event Resulting in a TEAE
Time Frame: Up to End of Study (up to Week 25)
|
Pulmonary evaluations included pulmonary function tests and pulse oximetry.
Clinically significant changes were to be reported as adverse events.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
|
Up to End of Study (up to Week 25)
|
Number of Participants With a Clinical Laboratory Abnormality Leading to an AE
Time Frame: Up to End of Study (up to Week 25)
|
Laboratory parameters included hematology (hematocrit, hemoglobin, red blood cell count, white blood cell count with differential [neutrophils, lymphocytes, monocytes, eosinophils, basophils], and platelet count); serum chemistries (blood urea nitrogen, creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total protein, sodium, potassium, bicarbonate, calcium, chloride, magnesium, inorganic phosphate, creatine kinase, lactate dehydrogenase, erythrocyte sedimentation rate, C-reactive protein, troponin, myoglobin, insulin-like growth factor 1, and cholesterol [(nonfasting]); urinalysis (color, pH, specific gravity, protein, glucose, ketones, and blood).
Clinically significant laboratory abnormalities were based upon Investigator's discretion.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
|
Up to End of Study (up to Week 25)
|
Number of Participants With Vital Sign Abnormality Resulting in a TEAE
Time Frame: Up to End of Study (Up to Week 25)
|
The vital sign parameters that were evaluated included heart rate, systolic and diastolic blood pressure, and respiration rate as well as temperature.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
|
Up to End of Study (Up to Week 25)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Manual Muscle Testing (MMT) Score at Week 14
Time Frame: Baseline, Week 14
|
MMT (muscle strength) was graded on a scale from 0 (no contraction palpable) to 5 (normal strength).
Decreased muscle strength was indicated by a decreased score.
|
Baseline, Week 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kelly Blackburn, aTyr Pharma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2015
Primary Completion (Actual)
October 5, 2016
Study Completion (Actual)
October 5, 2016
Study Registration Dates
First Submitted
September 28, 2015
First Submitted That Met QC Criteria
October 15, 2015
First Posted (Estimated)
October 19, 2015
Study Record Updates
Last Update Posted (Actual)
October 19, 2023
Last Update Submitted That Met QC Criteria
September 26, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATYR1940-C-004
- 2015-001910-88 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limb-Girdle Muscular Dystrophies
-
Wake Forest University Health SciencesMuscular Dystrophy AssociationCompletedMuscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)United States
-
University Hospital of North NorwayUniversity of Tromso; Norwegian Muscle Disease Association (FFM); Norwegian National... and other collaboratorsActive, not recruitingMuscular Dystrophies | Limb Girdle Muscular Dystrophy | Limb Girdle Muscular Dystrophy, Type 2I | Limb Girdle Muscular Dystrophy R9 FKRP-relatedNorway
-
Assistance Publique - Hôpitaux de ParisRecruitingLimb Girdle Muscular DystrophiesFrance
-
ML Bio Solutions, Inc.RecruitingLimb-Girdle Muscular Dystrophy Type 2I (LGMD2I)United States, Netherlands, United Kingdom, Denmark, Australia, Italy, Norway
-
Linda Pax LowesRecruitingLimb-Girdle Muscular Dystrophy Type 2A | Limb-Girdle Muscular Dystrophy, Type 2EUnited States
-
Virginia Commonwealth UniversityUniversity of Colorado, Denver; Washington University School of Medicine; University... and other collaboratorsRecruitingLimb Girdle Muscular Dystrophy | Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A | Limb Girdle Muscular Dystrophy Type R1 | LGMD2AUnited States, United Kingdom
-
Nationwide Children's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedLimb-Girdle Muscular DystrophyUnited States
-
IRCCS San Camillo, Venezia, ItalyUniversita di Verona; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico and other collaboratorsEnrolling by invitationCalpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2AItaly
-
Sarepta Therapeutics, Inc.Active, not recruiting
-
Nationwide Children's HospitalMyonexus TherapeuticsRecruitingLimb-Girdle Muscular Dystrophy, Type 2EUnited States
Clinical Trials on ATYR1940
-
aTyr Pharma, Inc.CompletedFacioscapulohumeral Muscular Dystrophy | Limb Girdle Muscular DystrophyUnited States, Denmark, Italy
-
aTyr Pharma, Inc.CompletedFacioscapulohumeral Muscular Dystrophy (FSHD)United States, Netherlands, France, Italy
-
aTyr Pharma, Inc.CompletedFacioscapulohumeral Muscular Dystrophy (FSHD)United States, France, Italy
-
aTyr Pharma, Inc.CompletedFacioscapulohumeral Muscular DystrophyUnited States, Italy, Netherlands